QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.009738v1 34/8/1277    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeda, S. Articles by Yamada, H. Search for Related Content PubMed PubMed Citation Articles by Takeda, S. Articles by Yamada, H.

SHORT COMMUNICATION

INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE

Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (S.T., Y.K., Y.I., Y.N., H.Y.); Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University, Adelaide, Australia (P.I.M.); and School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, Nobeoka, Japan (K.O.)

Glucuronidation of morphine in humans is predominantly catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). Since our recent research suggested that cytochrome P450s (P450s) interact with UGT2B7 to affect its function [Takeda S et al. (2005) Mol Pharmacol 67:665–672], P450 inhibitors are expected to modulate UGT2B7-catalyzed activity. To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). Among the inhibitors tested, ketoconazole was the most potent inhibitor of both M-3-G and M-6-G formation by human liver microsomes. The others were less effective except that nifedipine exhibited an inhibitory effect on M-6-G formation comparable to that by ketoconazole. Neither addition of NADPH nor solubilization of liver microsomes affected the ability of ketoconazole to inhibit morphine glucuronidation. In addition, ketoconazole had an ability to inhibit morphine UGT activity of recombinant UGT2B7 freed from P450. Kinetic analysis suggested that the ketoconazole-produced inhibition of morphine glucuronidation involves a mixed-type mechanism. Codeine potentiated inhibition of morphine glucuronidation by ketoconazole. In contrast, addition of another substrate, testosterone, showed no or a minor effect on ketoconazole-produced inhibition of morphine UGT. These results suggest that 1) metabolism of ketoconazole by P450 is not required for inhibition of UGT2B7-catalyzed morphine glucuronidation; and 2) this drug exerts its inhibitory effect on morphine UGT by novel mechanisms involving competitive and noncompetitive inhibition.

This article has been cited by other articles:

				S. Takeda, K. Misawa, I. Yamamoto, and K. Watanabe Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis Drug Metab. Dispos., September 1, 2008; 36(9): 1917 - 1921. [Abstract] [Full Text] [PDF]

				S. Klieber, S. Hugla, R. Ngo, C. Arabeyre-Fabre, V. Meunier, F. Sadoun, O. Fedeli, M. Rival, M. Bourrie, F. Guillou, et al. Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans Drug Metab. Dispos., May 1, 2008; 36(5): 851 - 862. [Abstract] [Full Text] [PDF]

				T. N. Operana and R. H. Tukey Oligomerization of the UDP-glucuronosyltransferase 1A Proteins: HOMO- AND HETERODIMERIZATION ANALYSIS BY FLUORESCENCE RESONANCE ENERGY TRANSFER AND CO-IMMUNOPRECIPITATION J. Biol. Chem., February 16, 2007; 282(7): 4821 - 4829. [Abstract] [Full Text] [PDF]